康希諾生物(06185.HK)股東減持逾360萬股A股
康希諾生物(06185.HK)(688185.SH)公布,於今年9月6日至12月5日期間,股東上海禮安透過集中競價交易和大宗交易,減持214.46萬股A股,減持價格介乎273.46至299.01元人民幣(下同),套現6.04億元。
另一股東蘇州禮泰於同一期間以同樣方式,減持145.78萬A股,減持價格介乎273.46至298.54元,套現4.09億元。上海禮安和蘇州禮泰為8月公布股東減持計劃的一致行動人。
是次減持計劃為公司股東根據自身需求進行的減持,實施主體不是公司控股股東,不會導致公司控股權發生變更,亦不會對公司治理結構及持續經營產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.